the orbitofrontal cortex that exhibits reduced behavioral inhibition, and the amygdala that is related to elevated impulsive behavior ( • ▶ Fig. 1a ).
Introduction ▼
Mood disorder is mainly characterized by a disturbance in a patient ' s mental well-being and includes major depressive disorder (MDD) and bipolar disorder. MDD is regarded as a leading cause of death world-wide with an estimated prevalence of 16 % in the United States [26, 39] . Neuropsychiatry already has identifi ed several macroanatomic brain structures and circuits by imaging studies and deep brain stimulation that are involved in the clinical phenomenology of mood disorders [3, 13, 35 -38, 47] : the prefrontal cortex that is responsible for impaired cognitive operations, the nucleus accumbens that is related to loss of hedonic states, the hippocampus with its memory dysfunctions, the striatal complex that is involved in reduced psychomotor action, of pro-infl ammatory cytokines. The stress response is regulated by the monoamine system, and disturbed monoamine transmission therefore impairs the regulation of stress responses. Thus, functional disorders of monoamine transmission, the HPA axis, and stress together contribute to MDD [51] . Two types of monoamines, norepinephrine and serotonin, have been the primary subject of investigation in the context of MDD. In comparison, dopamine (DA) has attracted less attention, although DA transmission is very important for the disorder as well. For instance, one of the 2 required symptoms of MDD in the criteria of the Diagnostic and Statistical Manual of Mental Disorders [1] is anhedonia with a prevalence of almost 40 % among MDD patients [46] . Anhedonia is the inability to experience enjoyment from activities that had been pleasurable before, and a reduction in DA transmission in the nucleus accumbens has been suggested as the cause [3, 38, 75 -77] . Because DA plays an important role in motivation and reward, the reduction in DA transmission, and the correspondingly reduced reward, can directly contribute to comorbidity between drug use and MDD [42] . Indeed, this association has been reported for quite some while [9, 58, 59] : MDD is diagnosed in about 30 % of cocaine addicts, and about 10 % of MDD patients have drug use disorders [61, 73] . Diff erent causalities have been suggested for the interaction between drug use disorders and a depressive disorder. One hypothesis suggests that neuronal adaptation is caused by chronic drug use due to frequent over-stimulation of brain reward pathways, and that drug withdrawal can therefore lead to depressive symptoms such as anhedonia [10, 16] . Another possible causality (called the self-medication hypothesis ) is that use of psychostimulants by MDD patients is an intentional strategy for improving their mental states [27, 34] . Other suggested mechanisms purport that drug use causes stress which then induces MDD or that drug use disorders share specifi c underlying processes with MDD. Such mechanisms are far from clear and may be complicated. However, these disorders have the DA system in common. In addition to the critical roles of DA in moti-vation and reward, as well as its contribution to anhedonia, indirect support for the involvement of DA comes from pharmacological observations. Reserpine depletes monoamine and can cause depressive symptoms in some patients. Iproniazid inhibits the degradation of monoamine by monoamine oxidase and improves depressive moods, while imipramine blocks the reuptake of monoamine and can have an antidepressant eff ect. While these observations are mainly associated with norepinephrine and serotonin, DA also belongs to the class of monoamines and shares almost the same metabolic pathway with norepinephrine. In fact, DA is the precursor of norepinephrine. Thus, antidepressant drugs should be expected to act on the DA system, especially by interfering with DA reuptake. Taking these fi ndings into account, the DA system and its transmission might be of crucial importance for the comorbidity of drug use disorders in MDD [65] . Although drug use disorders have been studied for a long time, our understanding of its governing processes is still rather limited. One underlying mechanism seems to be the synaptic plasticity of neuronal pathways that are involved in reward and learning, and a corresponding hypothesis states that addictive drug use is a form of " pathological learning " [22, 23, 25] . Synaptic plasticity is the capability of a synapse to adjust its connection strength by changing the amount of released neurotransmitters and / or modifying the effi cacy of its response to neurotransmitter stimulation [15] . The intensity of a response to neurotransmitters is determined by the density of postsynaptic receptors and by receptor conductance. In this study, we focus on the DA system and the eff ects of DA transmission on synaptic plasticity, which is hypothesized as an underlying mechanism for addictive drug use. The nucleus accumbens (NAc) is selected as locus of interest because the mesolimbic DA pathway is critical to reward and addictive drug use [69] . NAc is located in the ventral striatum and receives inputs for basal ganglia, and it is a component of the important cortico-striato-pallido-thalamo-cortical loop. In addition to dopamine input, NAc also receives glutamate projections from the cortex that can aff ect eff ects of DA transmission on synaptic plasticity. The mechanisms for regulating synaptic plasticity involve both sides of a synapse, that is, the presynapse and the postsynapse. Metabolic processes in the presynapse determine the amount of released neurotransmitters through the control of enzymatic reactions and the recycling of neurotransmitter between diff erent compartments. On the postsynaptic side, the density and conductance of receptors are regulated by second messenger systems and activity profi les of kinases and phosphatases. These regulatory mechanisms quantitatively and dynamically govern the resultant synaptic plasticity in a complex manner that exceeds the intuition of the human brain and necessitates support of a mathematical model. In the future, this model of synaptic plasticity in the comorbidity between drug use disorders and MDD will become even more complex when the roles of acetylcholine, serotonin and norepinephrine are merged with the present focus on dopamine.
Biochemical and Physiological Considerations ▼
Nerve cells in NAc are mainly medium spiny neurons that receive several neurotransmitters, including dopamine and glutamate. Dopamine binds to its D 1 and D 2 receptors on the postsynaptic membranes of NAc neurons and activates or inhibits a second messenger system (the cAMP system) which regulates the activity of protein kinase A (PKA) and the activity of protein phosphatase-1 (PP1). Glutamate binds to its ionotropic receptors ( e. g. , AMPA and NMDA receptors) and regulates the calcium fl ux into the postsynapse. This calcium fl ux in turn regulates the activity of Ca 2 + / calmodulin-dependent protein kinase (CaMKII) and the activity of protein phosphatase 2A (PP2A). These kinases and phosphatases control phosphorylation and dephosphorylation of AMPA receptors, and the density and conductance of these receptors are representations of the synaptic plasticity of GABAergic medium spiny neurons in the striatum ( • ▶ Fig. 1b -c ) .
Thus, the fi rst component of the model addresses processes in the presynapse, which include neurotransmitter production, storage, recycling, and degradation. In the case of dopamine (DA), several processes and mechanisms are critical, namely: DA synthesis, catalyzed by the enzyme tyrosine hydroxylase (TH); the packaging of DA into vesicles through vesicular monoamine transporters (VMAT2); the degradation of DA by the enzyme monoamine oxidase (MAO); and the reuptake of DA by dopamine transporters (DAT). These processes are shown in • ▶ Fig. 2a . The dynamics of glutamate is not modeled here. Instead, glutamate signals are simply represented by their main eff ect, which is the infl ux of calcium into the postsynapse. Fig. 2c ).
AMPARs can be inserted into the membrane and removed from it based on their phosphorylation states, which are controlled by kinases and phosphatases. A buff er of AMPARs, controlled through synthesis and degradation, acts as a supply and storage unit for cytosolic AMPARs and communicates with the pool of membrane-associated AMPARs. Controlled by these mechanisms, membrane-associated AMPARs modify the synaptic efficacy of medium spiny neurons.
Modeling Methods ▼
The model is set up with ordinary diff erential equations (ODE) of biochemical reactions and signal transduction processes that describe the 3 components and ultimately connect dopamine and glutamate signals to synaptic plasticity of GABAergic medium spiny neurons. It is partially based on earlier models from our lab as well as from other groups. Specifi cally, the components of the system model include sub-modules for dopamine metabolism in the presynapse [48, 49] , signal transduction in the postsynapse [2, 14, 31, 50] , and traffi cking of AMPA receptors [8, 18, 41] ( • ▶ Fig. 1b ). These modules were adapted and integrated into a single model that accounts for signals of dopamine and glutamate, their transduction in medium spiny neurons, and their control of AMPA receptors, which are used as indicators of synaptic plasticity of medium spiny neurons in the striatum. In the following sections, we review the 3 component modules: 
Fig. 1c
Mechanisms within the postsynapse that integrate dopamine and glutamate signals from diff erent presynaptic cells and ultimately lead to synaptic plasticity in neurons of the nucleus accumbens. Specifi cally, dopamine and glutamate signals aff ect the activity of various kinases and phosphatases, which interact with each other and with DARPP-32. Activity profi les of kinases and phosphatases regulate phosphorylation and dephosphorylation of AMPAR, whose density and conductance modify synaptic plasticity of GABAergic medium spiny neurons. Ovals attached to DARPP-32 and denoted as Thr 34 and Thr 75 indicate phosphate groups at two threonine residues; their numbers refer to positions in the rat sequence. Blunted lines represent inhibition signals. Green and red boxes are kinases and phosphatases, respectively.
AMPA receptors. Subsequently, we will discuss pertinent specifi cs of module integration and additional issues of model design.
Neurotransmitter dynamics and role of amphetamine :
The neurotransmitter dopamine is synthesized from its precursor L-DOPA, which is produced from tyrosine ( • ▶ Fig. 2a ). Most synthesized dopamine is packed into vesicles for storage and for later release into the synaptic cleft. Released dopamine can bind to its receptors on the postsynaptic membrane and transfer neuronal signals. As an alternative to receptor binding, dopamine transporter (DAT) can carry the released dopamine back into the presynaptic terminal for recycling. Within the terminal and the synaptic cleft, dopamine can be enzymatically converted into other metabolites. The dopamine signal leaving the presynapse is composed of a basal level and the stimulated release in response to electrical signals received by the presynaptic membrane. The psychostimulant amphetamine increases the release of dopamine from vesicles into the cytosol through VMAT2 and to the synaptic cleft via DAT [66] . At the same time, it inhibits the enzyme MAO, which degrades excess dopamine, and promotes synthesis of dopamine through activation of the enzyme tyrosine hydroxylase (TH) [66] . Glutamate is produced and degraded in diff erent neurons and glia cells. For simplicity, glutamate signals are represented here by their main eff ect, namely the infl ux of calcium into the postsynapse.
Signal transduction :
In the presence of dopamine, the D 1 receptors are activated while the D 2 receptors are inhibited. Since the D 1 and D 2 receptors regulate cAMP antagonistically, the eff ects of D 2 receptors in response to dopamine stimulation can be represented indirectly and in fi rst approximation through the function of D 1 . Because mechanistic details of the antagonistic action are not known quantitatively, and in order to keep our model as simple as feasible, we therefore include only dopamine D 1 receptors in our model. When dopamine binds to its postsynaptic receptors of D 1 subtype, a G-protein based mechanism triggers a second-messenger cAMP system ( • ▶ Fig. 2b ). The cAMP system in turn activates protein kinase A (PKA). PKA then phosphorylates DARPP-32 at a specifi c threonine residue (DARPP-32-Thr34, where 34 refers to the position in the rat sequence) and thereby converts it into a potent inhibitor of protein phosphatase-1 (PP1). Glutamate binds to its own ionotropic receptors ( e. g. , AMPAR and NMDAR) and induces Ca 2 + fl ux into the cell. The elevation of Ca 2 + activates protein phosphatase 2B (PP2B), which dephosphorylates DARPP-32 and reduces its inhibition of PP1. Meanwhile, Ca 2 + infl ux activates phosphorylation of DARPP-32 by cyclin-dependent kinase 5 (CDK5) at another threonine residue (DARPP-32-Thr75), which inhibits the activity of PKA.
Traffi cking of AMPA receptors : In response to dopamine and glutamate signals and their eff ects on DARPP-32, the kinases and phosphatases aff ect the phosphorylation and dephosphorylation state of AMPARs and thus their membrane insertion or removal, which in turn modifi es the synaptic effi cacy of medium spiny neurons ( • ▶ Fig. 2c ). The kinase PKA can phosphorylate AMPAR at site Ser845, while another kinase CaMKII can phosphorylate site Ser831. Both sites can be dephosphorylated by the phosphatase PP1 and the protein phosphatase PP2A. The double phosphorylation of AMPAR enables the binding of an anchor and the insertion of cytosolic AMPAR into the postsynaptic membrane. The unphosphorylated form of AMPAR separates from the anchor and moves back into the cytosol. A buff er of AMPARs, which is controlled by their synthesis and degradation, acts as a supply and deposit of cytosolic AMPAR. Thus, AMPARs travel between membrane, cytosol, and the buff er in diff erent phosphorylation states.
Model equations :
The integrative model for synaptic plasticity of GABAergic medium spiny neurons in the striatum is set up based on ODEs and the law of mass action. Specifi cally, all reactions are represented in the form of an enzymatic reaction (Eq. 1) or a simple binding reaction (Eq. 2):
Features regarding dopamine metabolism in the presynapse were taken directly from [48] and are not repeated here. The remaining reactions and their kinetic details are listed in • ▶ Table 1 -3 in the appendix. Initial conditions for the diff erential equations are presented in • ▶ Table 4 . Altogether, the integrated model consists of 121 ordinary diff erential equations. After typical diagnostics of stability and robustness ( e. g. , [71, 72] ), which showed that the model behaves properly, we simulated the responses of the system to various dopamine and glutamate signals and in the context of comorbid drug use in MDD. These simulations included diff erent scenarios of neurotransmitter depletion, low frequency stimulation (LFS), and high frequency stimulation (HFS). Dopamine and glutamate signals were considered separately as well as in combination. Subsequently, drug injection of the psychostimulant amphetamine was simulated. Finally, we perturbed mechanisms that have the potential of critically aff ecting synaptic plasticity and observed their eff ects on the performance of the system in response to various input signals.
Results

▼ Synaptic plasticity caused by dopamine and glutamate
A necessary step between model construction and application is the testing and validation of the model against biological and clinical observations. In the current context, these observations consist primarily of electrophysiological data. Specifi cally, the following observations of changes in synaptic effi cacy in response to diff erent stimuli of dopamine and glutamate are important. [56] . We simulated all these diff erent signal scenarios and compared simulated results with electrophysiological observations. In these simulations, the basal levels of dopamine and calcium cation were set to 10 nM and 50 nM, respectively. The stimulated dopamine level maximally reached 2 μ M, while activated calcium cation maximally reached 5 μ M. Synaptic plasticity was represented by the ratio of the number of membrane AMPARs after and before a particular stimulus. In consideration of the conductance diff erence between diff erent phosphorylated forms of membrane AMPARs, we used a formula to calibrate the computation of synaptic plasticity. In this formula, single phosphorylation raises the basal conductance by 50 % , while double phosphorylation is assumed to result in twofold basal conductance.
Overall, the results of the model simulations demonstrated good consistency with electrophysiological observations ( • ▶ Fig. 3 ).
The model simulations identifi ed 2 interesting phenomena of potential importance. First, they showed that changes in synaptic plasticity are mostly of short duration, with a typical time frame of about 10 min. This result is consistent with the observation that synaptic potentiation caused by substantia nigra (or the ventral tegmental area) stimulation mostly lasts for 10 -15 min [56] . The second interesting result is a temporary synaptic depression, which precedes synaptic potentiation in cases of concurrent dopamine and glutamate signals. We are not aware of clinical observations of this eff ect.
Synaptic plasticity caused by amphetamine and comorbidity with MDD
To study the eff ect of the psychostimulant amphetamine on synaptic plasticity of GABAergic medium spiny neurons, we incorporated the mechanisms triggered by amphetamine into the model of dopamine metabolism and compared its output with experimental observations [78] . A comparison of results showed that the model produced dynamic responses of extracellular dopamine very similar to those measured by the brain dialysis (results not shown). Accounting for the eff ects of amphetamine in the model, we also simulated eff ects of diff erent amounts of amphetamine on synaptic plasticity of GABAergic medium spiny neurons, with dosages varying from 0.1 mg / kg to 5 mg / kg, a range that corresponds to street use and medical treatments. The eff ective period of 0.5 mg / kg amphetamine turned out to be longer than 2 h, thus requiring an increased time window for the simulations. As the results show, a single injection of 0.5 mg / kg amphetamine can potentiate synaptic effi cacy to a level that corresponds to about 3 times the basal level ( • ▶ Fig. 4a, b ) . The system behaves quasi in a bistable way, and the synaptic potentiation lasts for over 2 h. As there is suspected comorbidity between drug use disorders and MDD, we also studied the eff ect of the psychostimulant amphetamine on synaptic plasticity within an MDD-impaired DA system. Since antidepressants block the reuptake of monoamines, we simulated the opposite of this process in order to refl ect MDD, namely an increased (doubled) activation of DAT. We then challenged the impaired system with a single injection of 0.5 mg / kg amphetamine ( • ▶ Fig. 4c , d ) . The results show that activation of DA reuptake impairs DA transmission and causes a reduced reward of amphetamine in MDD. Furthermore, the impairment of DA transmission leads to a reduced synaptic potentiation eff ect of the psychostimulant. Another intervention causing reduced reward is the application of dopamine D 1 antagonists (e. g., SCH 39166), which in a model simulation causes an alteration of amphetamine eff ects on synaptic plasticity (data not shown).
Eff ects of various mechanisms on synaptic plasticity
In an additional set of simulations of a diff erent type, we perturbed mechanisms in the system that we expected to be potentially important to synaptic plasticity of GABAergic medium spiny neurons. These prescreened mechanisms included: the Fig. 2b ).
Besides these mechanisms in the postsynapse, we tested processes in the presynapse that were identifi ed as particularly critical in the context of psychostimulants. Specifi cally, it has been suggested that amphetamine aff ects the synthesis, storage, recycling, and degradation of dopamine (red arrows in • ▶ Fig. 2a ).
These processes are primarily related to the function of VMAT2, 
Fig. 3
Typical synaptic plasticity of GABAergic medium spiny neurons in response to various stimuli to the corticostriatal projections and the substantia nigra (or the ventral tegmental area). Time is given in units of seconds, while synaptic plasticity is expressed as the ratio of the number of membrane-associated AMPARs after and before a stimulus (blue lines), and as ratio of conductance of membrane-associated AMPARs (green lines).
DAT, MAO-B, and catechol O-methyltransferase (COMT)
. Therefore, we perturbed these components before applying amphetamine and studied their eff ects on synaptic plasticity. Perturbations of the involved mechanisms consisted of 10-fold activation and inhibition, which were implemented per multiplication of the relevant rate constants by 10 or 0.1, respectively. Fig. 5 b ) .
(II) PKA -PP2A -DARPP-32-Thr75 -PKA : PKA activates PP2A, which is the phosphatase responsible for removal of the phosphate at threonine residue 75 of DARPP-32. Since DARPP-32 phosphorylated at Thr75 inhibits PKA, these processes together form a positive feedback loop ( • ▶ Fig. 6 a ) . The simulation results
show that inhibition of this positive feedback loop can counteract the synaptic depression eff ect of glutamate signals ( • ▶ Fig. 6 b ) .
For dopamine signals, however, activation of this loop enhances synaptic potentiation. In response to concurrent dopamine and glutamate signals, inhibition of this loop -rather than its activation -counteracts the synaptic depression eff ect of glutamate signals. Quantitatively, this positive feedback loop contributes more significantly to the eff ects of dopamine rather than glutamate.
(III) Glutamate -PP2B -PP1 vs. Glutamate -CaMKII -PP1 : Glutamate activates phosphatase PP2B, which removes phosphate at Thr34 residue of DARPP-32. Because this dephosphorylation releases DARPP-32 inhibition of PP1, glutamate activates PP1 through this pathway. However, the autophosphorylation of the kinase CaMKII is also activated by glutamate and then inhibits PP1. Therefore, the eff ect of glutamate on synaptic plasticity can vary, depending on the relative magnitudes of its activation and its inhibition of PP1 ( • ▶ Fig. 7a ). Inhibition of PP1 can be obtained through activation of the glutamate -CaMKII -PP1 pathway, which shows enhanced eff ects of both dopamine and glutamate signals. By contrast, inhibition of the glutamate -CaMKII -PP1 pathway diminishes the normal eff ects of both dopamine and glutamate signals so that corticostriatal HFS induces synaptic potentiation instead of synaptic depression ( • ▶ Fig. 7b ). In contrast to the glutamate -CaMKII -PP1 pathway, the glutamate -PP2B -PP1 pathway has a less signifi cant impact on synaptic plasticity.
(IV) PKA -DARPP-32-Thr34 -PP1 vs. PKA -I1 -PP1 : PKA indirectly inhibits PP1 through 2 pathways: one is PKA -DARPP-32-Thr34 -PP1 and the other is PKA -I1 -PP1 ( • ▶ Fig. 8a ). It is interesting to investigate their relative signifi cance for the regulation of synaptic plasticity. Our simulations show that PKA inhibition of PP1 through DARPP-32-Thr34 is more eff ective than inhibition through the PKA -I1 -PP1 pathway ( • ▶ Fig. 8b ).
Increased PKA inhibition of PP1 potentiates dopamine-induced synaptic plasticity, while reduced inhibition of PP1 by PKA diminishes dopamine-induced synaptic potentiation.
Perturbations aff ecting VMAT2, DAT, MAO-B, or COMT :
A perturbation aff ecting each of these molecules was applied before a single application of 0.5 mg / kg amphetamine. Our simulations showed that the enzymes MAO-B and COMT are less signifi cant than the transporters VMAT2 and DAT with respect to amphetamine eff ects on synaptic plasticity. Activation of DAT diminishes synaptic potentiation caused by amphetamine, while DAT inhibition enhances it (results not shown). 
Conclusions and Discussion ▼
MDD patients have a strongly elevated risk of developing comorbidity with drug use disorders. Aggravating the situation, the model presented here suggests that the reward from drug use decreases in MDD-impaired DA systems, which will likely lead to the consumption of even higher doses of psychostimulants. Without treatment, the relapse rate among drug abusers within one year is as high as 90 % [29] . One reason for this unfortunate situation may be an insuffi cient understanding of their underlying mechanisms. It has been suggested that synaptic plasticity might be one of such mechanisms. Therefore, it is important to characterize synaptic plasticity in detail. Specifi cally, it seems useful to screen and manipulate those mechanisms that are potentially critical to synaptic plasticity and to explore means of altering and correcting drug-caused modifi cations. Of course it is diffi cult to study alterations and manipulations of the reward system in a systematic fashion in situ , and the reward system itself is too compli-cated to use intuition as the sole means of explanation. By contrast, a computational model of the system, once constructed and validated, is easily simulated, manipulated with precisely targeted interventions and optimized toward a desirable goal. In this paper, we present how such an analysis can be performed. Two molecular mechanisms are primarily utilized for synaptic plasticity: (1) modifi cation of existing proteins; and (2) regulation of gene transcription and translation into new protein [54, 62] . The second mechanism accounts for long-lasting eff ects, but requires a longer response time than the fi rst mechanism does, because gene expression is a much slower process than metabolic regulation and protein degradation.
In this study, we focused on the short-term eff ects of 2 neurotransmitters, dopamine and glutamate, and on alterations of their eff ects under drug abuse. Under normal conditions, dopamine and glutamate eff ects last for about 10 -20 min, but this time period extends to over 2 h under the infl uence of amphetamine. Glutamate signals are released by neurons projected from the cortex to the striatum, while dopamine signals come from striatal projections of dopaminergic neurons. In the striatum, the GABAergic medium spiny neurons typically respond to dopamine stimuli with synaptic potentiation and to glutamate signals with synaptic depression. Under concurrent dopamine and glutamate signals, the synaptic plasticity varies with input combinations ( • ▶ Fig. 9 ). Interestingly, a single dose of 0.5 mg / kg amphetamine makes synaptic plasticity of medium spiny neurons behave like a quasi-bistable system. The eff ects of dopamine and glutamate signals on synaptic plasticity depend on several important processes. The positive feedback loop of PKA -PP2A -DARPP-32-Thr75 -PKA is important for eff ects of dopamine on synaptic plasticity. The negative feedback loop of PKA -PDE -cAMP -PKA is also critical with respect to dopamine, because inhibition of this module eliminates responses of the system to dopamine. Drug abuse commonly causes dopamine release in the NAc, and behavioral observations indicate that the mesolimbic dopamine pathway is directly involved in drug rewards [12] . As a consequence, these 2 feedback loops should be further investigated, because their alteration might have the potential of reversing drug use disorders. The glutamate signal from the cortex is similarly critical for drug-induced adaptations of neuronal behavior. Our results suggest that glutamate relies more on the glutamate -CaMKII -PP1 pathway than on the glutamate -PP2B -PP1 mechanism with respect to the regulation of synaptic plasticity. Dopamine and glutamate signals interact with each other through multiple pathways. One of these pathways is the inhibition of PP1 by PKA. The model simulations indicate that the indirect inhibition of PP1 through DARPP-32-Thr34 might actually be more eff ective than the inhibition of PP1 through I1. Our current study focuses on short-term plasticity, which is important for early responses to drug exposures as well as the induction of long-term adaptations. However, drug use disorders are not formed immediately after an initial drug abuse. It requires chronic drug abuse and its time frame might range from weeks to months to years. These time scales most likely allow additional, signifi cant contributions to synaptic plasticity from altered gene transcription and protein translation, as described above. One of the relevant molecules which control gene expression in this context is the transcription factor CREB (cAMP responsive elementbinding protein), which, like some other components of long-term responses, will be analyzed in future work. The mathematical model of synaptic plasticity of GABAergic medium spiny neurons that we presented here permits targeted manipulations and unlimited explorations of what-if scenarios. In particular, it allows comparative analyses between normal responses and responses under the infl uence of psychostimulants, in the absence or presence of MDD-induced impairments of the DA system. As we have shown, such analyses can characterize the relative importance of diff erent components, such as the various control loops within the system. Since reward mechanisms activated by psychostimulants could be crucial in establishing addictive comorbidity in patients with MDD, this model might become an aid for targeting specifi c processes and modules within the reward system and lead to a better understanding and potential treatment of the comorbidity between drug use disorders and MDD.
Scenarios of Synaptic Plasticity [DA]
[Glu] Fig. 2c for abbreviations) . : For a chemical reaction, K f is the rate constant for the forward process, K b is the rate constant for the backward process, while K c is the rate constant for the catalytic step in a Michaelis-Menten kinetics stant for the forward process, K b denoting the rate constant for the backward process, and K c denoting the rate constant for the catalytic step in a Michaelis-Menten kinetics. Table 2 Reactions and rate constants of DARPP-32 phosphorylation in dendrites of medium spiny neurons in the striatum (see legend of • ▶ Fig. 2c for abbreviations Table 3 Reactions and rate constants of AMPAR traffi cking, AMPAR phosphorylation, and AMPAR dephosphorylation in the postsynapse of striatal projection neurons (see legend of • ▶ Fig. 2c for abbreviations) . This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Table 4 Initial values for the DARPP-32 phosphorylation system in dendrites of medium spiny neurons in the striatum (see legend of • ▶ Fig. 2c for abbreviations).
HFS
Reaction K f (nM − 1 .s − 1 ) # K b (s − 1 ) K c (s − 1 ) Ref. D1 + DA ↔ D1_DA 1.1E − 3 10.0 [31] D1_DA + G α β γ ↔ D1_DA_G α β γ 6.0E − 4 1.0E − 3 [31] D1 + G α β γ ↔ D1_G α β γ 6.0E − 5 3.0E − 4 [31] D1_G α β γ + DA ↔ D1_DA_G α β γ 3.3E − 3 10.0 [31] D1_DA_G α β γ → D1_DA + G α GTP + G β γ 20.0 a [31] G α GTP → G α GDP 10.0 a [31] G α GDP + G β γ → G α β γ 100.0 [31] G α GTP + AC5 ↔ G α GTP_AC5 3.9E − 2 50.0 [31] G α GTP_AC5 + ATP ↔ G α GTP_AC5_ATP 1.3E − 4 2.6E − 1 [31] G α GTP_AC5_ATP ↔ G α GTP_AC5 +
Reaction
Molecule Concentration (nM)
